 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | morphine sulphate / Generic mfg., paclitaxel / Generic mfg.
Journal: Cannabinoid CB2 receptors in primary sensory neurons are implicated in CB2 agonist-mediated suppression of paclitaxel-induced neuropathic nociception and sexually-dimorphic sparing of morphine tolerance. (Pubmed Central) - Jun 19, 2024
LY2828360 (3?mg/kg per day i.p. x 8 days) delayed, but did not prevent, the development of paclitaxel-induced mechanical or cold allodynia in either CB2f/f or CX3CR1CRE/+; CB2f/f mice of either sex. Our findings have potential clinical implications.
- | Acomplia (rimonabant) / Sanofi, AM1710 - MAKScientific, Tetra Bio / Pharma
Preclinical, Journal: Blockade of CB1 or Activation of CB2 Cannabinoid Receptors Is Differentially Efficacious in the Treatment of the Early Pathological Events in Streptozotocin-Induced Diabetic Rats. (Pubmed Central) - Jan 9, 2023
These findings provide new knowledge regarding the differential efficacies of the cannabinoids, when administered topically, in the treatment of ESDR. Cannabinoid neuroprotection of the diabetic retina in ESDR may prove therapeutic in delaying the development of the advanced stage of the disease.
- | morphine sulphate / Generic mfg.
Preclinical, Journal: Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy. (Pubmed Central) - Nov 24, 2022
The present studies indicate that CB2 activation may alleviate HIV-associated antiretroviral neuropathy and identify a previously unreported mechanism through which CB2 activation produces antinociceptive efficacy. Our results also provide the first evidence that a CB2 agonist can reverse established morphine tolerance and demonstrate that CB2 localized to peripheral sensory neurons mediates the opioid tolerance sparing efficacy of CB2 agonists.
- | AM1710 - MAKScientific, Tetra Bio / Pharma, LY2828360 / Eli Lilly
Preclinical, Journal: A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. (Pubmed Central) - Apr 20, 2022
Quantification of the EGFP signal revealed that Langerhans cells were dynamically increased in the epidermis after paclitaxel treatment. Our studies implicate CB2 expressed in previously unrecognized populations of skin cells as a potential target for suppressing chemotherapy-induced neuropathic nociception.
- | AM1710 - MAKScientific, Tetra Bio / Pharma
Preclinical, Journal: Peripherally administered cannabinoid receptor 2 (CBR) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. (Pubmed Central) - Mar 29, 2022
In rat, intrathecal AM1710 and AM1241 reduced spinal and DRG TRPV1 expression, with CCL2-astrocyte and -microglial co-expression. These data support that CBR agonists can impact spinal and DRG TRPV1 expression critical for anti-allodynia.
- || PF-3845 / Pfizer, AM1710 - MAKScientific, Tetra Bio / Pharma, URB597 / Exxel Pharma
Review, Journal: Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. (Pubmed Central) - Jun 29, 2021
Clinical evidence shows that smoked cannabis alleviates HIV-NP. Further research is needed to find out if non-psychoactive drugs that target the ECS and are delivered by other routes than smoking could be useful as treatment options for HIV-NP.
- | AM1710 - MAKScientific, Tetra Bio / Pharma
Preclinical, Journal: Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain. (Pubmed Central) - Jun 26, 2021
We conclude that CB R is dispensable for either peripheral or central anti-allodynic actions of AM1710 in neuropathic mice. Cannabinoid CB R agonists produce heightened spinal IL-10 which may be clinically relevant to successfully treat neuropathic pain.
- | AM1710 - MAKScientific, Tetra Bio / Pharma
Journal: Synthesis of Functionalized Cannabilactones. (Pubmed Central) - Nov 21, 2020
The two key cannabilactone prototypes AM1710 and AM1714 were obtained selectively in high overall yields and in a lesser number of synthetic steps when compared to our earlier synthesis. The new approach expedited the synthesis of cannabilactone analogs with structural modifications at the four potential pharmacophoric regions.